Navigation Links
Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine),Data Published in Pain Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Javelin Pharmaceuticals, Inc. (AMEX: JAV), a leading developer of novel products for pain control, today announced that its Phase 2 multi-dose study of Rylomine was published in Pain Medicine, the official journal of The American Academy of Pain Medicine. The article, entitled, "Analgesic Efficacy and Safety of Morphine-Chitosan Nasal Solution in Patients with Moderate to Severe Pain Following Orthopedic Surgery", was recently made available online and can found at the following link:

"Rylomine is one of three late stage drug development candidates in our pipeline that address large underserved markets for pain management. It employs a patented formulation of intranasal morphine in a simple disposable device that requires no programming or special patient education," said, Dr. Daniel B. Carr, CEO and CMO. "While still in development, Rylomine has potential to become the non-invasive approach of choice for administering intermittent doses of morphine for post-surgical pain in medically supervised settings. Morphine is the reference standard for treatment of post-surgical pain, as well as pain from trauma and diseases including cancer."

Top line data from the first of two pivotal post-surgical Phase 3 clinical trials of Javelin's Rylomine is anticipated this summer.

Orthopedic Surgeries

According to the United States Department of Health and Human Services, orthopedic operations make up approximately 10% (7.4 million) of the 73.4 million ambulatory and in-patient surgical procedures in the United States annually.

About Rylomine

Rylomine (intranasal morphine), is currently in Phase 3 development in the United States, for moderate-to-severe pain in supervised healthcare settings. It employs the patented and proprietary, Chysis(R) drug-delivery platform to adhere and regularize the kinet ics of morphine to and across the nasal mucosa. Each nostril can hold only 150-200 ul of administered drug candidate and requires approximately 15 minutes for the Rylomine to clear the nasal passages. This provides potential for substantial patient safety.

About Javelin Pharmaceuticals, Inc.

With US corporate headquarters in Cambridge, MA, and a European office in Cambridge, UK, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information, please visit the website at

Forward-looking Statement

This press release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA (and foreign equivalent) review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.



Javelin Pharmaceuticals, Inc.
Investor Relations & Media
Rick Pierce, 617-349-4500
VP Investor Relations
Corporate Communications
June Gregg, 617-349-4500
Fax: 617-349-4505


Related medicine technology :

1. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  Trovagene, Inc. (NASDAQ: TROV ... that Chief Executive Officer Antonius Schuh, Ph.D., is scheduled ... Annual Piper Jaffray Healthcare Conference. th ... York Palace Hotel in New York ... EST. Mr. Schuh will be available for one-on-one meetings ...
(Date:11/25/2015)... Nov. 25, 2015 USP 800 applies ... preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, physician ... The chapter also covers all entities which store, ... hospitals, other healthcare institutions, patient treatment clinics, physicians, ... --> --> What is the ...
(Date:11/25/2015)... , November 25, 2015 Developmental, commercial, ... role in boosting the profitability of pharmaceutical products, ... commercial, and regulatory/legal strategies all play a ... says GBI Research . --> ... play a key role in boosting the profitability of pharmaceutical products, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... , ... On November 23rd 2015 Cozy Products, a division of ... Cozy Products explains what this means for business moving forward. , The Tri Lite ... business model: to sell personal heaters that reduce energy consumption, are economical and keep ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s ... learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions ... 65 years, Brillianteen has been a treasured tradition for numerous families in the ...
(Date:11/25/2015)... Missouri (PRWEB) , ... November 25, 2015 , ... ... HEAL, will provide scholarships for people struggling with eating disorders as a result ... from the second annual event, held at Fox Run Golf Club in Eureka, ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely ... resulting in a way for homeless people to have a more dignified and ... new initiative whereby they are repurposing plastic bags into sleeping mats for the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
Breaking Medicine News(10 mins):